-
公开(公告)号：EP4419079A1
公开(公告)日：2024-08-28
申请号：EP22805823.6
申请日：2022-10-18
CPC分类号： A61K9/08 , A61K47/12 , A61K38/1774
-
公开(公告)号：EP4414035A2
公开(公告)日：2024-08-14
申请号：EP24178618.5
申请日：2014-12-19
申请人： Immutep S.A.S.
发明人： TRIEBEL, Frédéric
IPC分类号： A61P35/00
CPC分类号： A61K45/06 , A61K31/4745 , A61K31/555 , C07K14/70503 , C07K2319/3020130101 , A61K38/1774 , A61P35/00 , A61P43/00
摘要： Combined preparations for the treatment of cancer are described. The combined preparations comprise: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor. Methods for the treatment of cancer using the combined preparations are also described.
-
公开(公告)号：EP4408894A2
公开(公告)日：2024-08-07
申请号：EP22877473.3
申请日：2022-09-21
发明人： WANG, Benjamin , ZEINER, Gusti , GACEREZ, Albert , HERZIG, Eytan
IPC分类号： C07K16/30 , A61K38/20 , C07K14/725 , C07K19/00 , A61P35/00
-
公开(公告)号：EP3388079B1
公开(公告)日：2024-05-29
申请号：EP18174337.8
申请日：2016-03-24
CPC分类号： A61K38/00 , C07K14/70539 , A61K39/0011 , C07K14/7051 , C07K14/4748 , C07K2319/0020130101 , C07K14/47 , C07K2319/4020130101 , C07K14/4702 , C12N9/6491 , C12Y304/24 , A61P35/00 , A61P35/02 , A61P39/00 , A61K38/08 , A01N37/46 , A61K31/404 , A61K31/4745 , A61K31/519 , A61K31/675 , A61K38/06 , A61K38/1774 , A61K39/001102 , A61K39/001103 , A61K39/001148 , A61K39/001152 , A61K39/001154 , A61K39/001159 , A61K39/001162 , A61K39/001184 , A61K45/06 , A61K2039/5420130101 , A61K2039/5720130101 , A61K2039/57220130101 , A61K2039/58520130101 , A61P37/04 , A61P43/00 , C07K2319/5520130101 , C07K2319/6020130101 , C12N5/0093 , C12N5/0636 , C12N5/0693 , C12N2510/0020130101 , A61K39/4611 , C12N5/0646 , A61K39/4644 , C12N5/0638 , A61K39/00
-
公开(公告)号：EP3708587B1
公开(公告)日：2024-05-22
申请号：EP20169645.7
申请日：2016-11-23
IPC分类号： A61K39/00
CPC分类号： A61K38/1774 , A61K35/545 , C07K14/7051 , C07K14/4748 , C12N5/0636 , C07K2319/0220130101 , C07K2319/0320130101 , C12N2506/4520130101 , C12N2510/0020130101 , C07K16/2803 , C07K16/3092 , C07K2319/3320130101 , A61P35/00 , A61K39/461 , A61K39/4611 , A61K39/4631 , A61K39/4632 , A61K39/464402 , A61K39/464453 , A61K2239/2920230501 , A61K39/464417 , A61K39/4644 , A61K39/464429 , C12N5/0638
-
公开(公告)号：EP2908853B1
公开(公告)日：2018-12-05
申请号：EP13847469.7
申请日：2013-10-21
IPC分类号： A61K38/17 , C07K14/705
CPC分类号： A61K38/177 , A61K9/0014 , A61K9/0048 , A61K38/1774 , C07K14/70503 , C12N15/1138 , C12N2310/113 , C12N2310/141
摘要： The present invention relates to methods of treating a condition involving excessive adipogenesis. This method relates to selecting a subject having a condition involving excessive adipogenesis and administering to the selected subject a composition comprising a Thy1 protein or polypeptide fragment thereof, or an agent that enhances Thy1 expression, under conditions effective to treat the condition. The present invention also relates to isolated nucleic acid molecules encoding a Thy1 protein or the fragment thereof and pharmaceutical formulations including such a protein or fragment thereof or an agent that enhances Thy1 expression and a pharmaceutically acceptable carrier. The present invention also relates to methods of inhibiting adipogenesis and/or decreasing adipocyte size, as well as methods of screening a candidate compound for its ability to influence adipogenesis.
-
公开(公告)号：EP3402810A1
公开(公告)日：2018-11-21
申请号：EP16775169.2
申请日：2016-09-27
IPC分类号： C07K14/705 , A61K38/17 , C07K16/46
CPC分类号： C07K14/705 , A61K38/1709 , A61K38/1774 , A61K39/395 , C07K2319/30
摘要： The present invention refers to an inhibitor of T cell costimulation and/or activation and/or function for use in the treatment and/or prevention of cardiac pathologies, preferably heart failure diseases, and/or of related symptoms.
-
公开(公告)号：EP3380117A1
公开(公告)日：2018-10-03
申请号：EP16867445.5
申请日：2016-11-23
申请人： Cartherics Pty. Ltd.
发明人： BOYD, Richard , TROUNSON, Alan , KAWAMOTO, Hiroshi
IPC分类号： A61K39/00 , A61K35/17 , C07K19/00 , C12N5/0783
CPC分类号： A61K39/001153 , A61K35/17 , A61K35/545 , A61K38/1774 , A61K39/001102 , A61K2039/5158 , A61P35/00 , C07K14/4748 , C07K14/7051 , C07K14/70517 , C07K16/2803 , C07K16/3092 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N5/0636 , C12N5/0638 , C12N2506/45 , C12N2510/00
摘要： The present invention relates generally to a population of stem cells (e.g., iPSCs or HSCs) that comprise nucleic acids encoding a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, for example two distinct tumour antigenic determinants. The present invention is also directed to a population of T cells that co-express a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, such as two distinct tumour antigenic determinants. The cells of the present invention can be derived from chosen donors whose HLA type is compatible with significant sectors of the populations, and are useful in a wide variety of applications, in particular in the context of the therapeutic treatment of neoplastic conditions.
-
公开(公告)号：EP3359150A1
公开(公告)日：2018-08-15
申请号：EP16854166.2
申请日：2016-10-04
发明人： MOLINEAUX, Susan, M. , GROSS, Matthew, I , BROMLEY, Susan, D. , PARLATI, Francesco , BENNETT, Mark, K.
IPC分类号： A61K31/41 , A61K31/435 , A61P35/00 , A61P31/00 , A61P37/00
CPC分类号： A61K31/501 , A61K38/1774 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2818 , C07K16/2827 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
-
10.发明公开
公开(公告)号：EP3349792A1
公开(公告)日：2018-07-25
申请号：EP16778924.7
申请日：2016-09-14
发明人： SABZEVARI, Helen , METENOU, Simon
IPC分类号： A61K39/395 , C07K14/705 , C07K16/28 , C07K16/30 , C07K14/47 , A61K39/00
CPC分类号： C07K16/2803 , A61K38/1774 , A61K39/3955 , A61K2039/505 , A61K2300/00 , A61P35/00 , C07K14/4702 , C07K14/705 , C07K14/70503 , C07K16/2863 , C07K16/2896 , C07K16/3015 , C07K2317/73 , Y02A50/466
摘要： The present disclosure relates the combined effect of anti-CD155 [CD155, Nectin-like protein 5 (Nec1-5), Tage4, HVED, poliovirus receptor (PVR)] antibodies or anti TIGIT antibodies [TIGIT (T cell immunoreceptor with Ig and ITIM domains), WUCAM (Washington University cell adhesion molecule), Vstm3 (V-set and transmembrane domaincontaining protein 3), Vsig9 (V-set and immunoglobulin domain-containing protein 9)] with a TGF Beta 1 antagonist. The effect is measured by increased IFN-gamma production human breast adenocarcinoma cells. Use of combined antibodies /CD155 or TIGIT) with a TGF-Beta 1 antagon-ist to treat a patient with cancer is claimed.
-
-
-
-
-
-
-
-
-
搜索结果
578 条记录 (耗时 0.04 秒)
